Summit Partners Public Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Summit Partners Public Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-873,803	Closed	-$69.7M	–	192
2022 Q2	$69.7M	Sell	873,803 -84,178	-9%	-$7.97M	3.14%	4
2022 Q1	$101M	Sell	957,981 -105,255	-10%	-$10.3M	3.58%	3
2021 Q4	$115M	Sell	1,063,236 -25,702	-2%	-$2.8M	4.38%	1
2021 Q3	$119M	Buy	1,088,938 +175,443	+19%	+$18.2M	3.74%	2
2021 Q2	$85.5M	Sell	913,495 -29,898	-3%	-$2.75M	3.04%	2
2021 Q1	$86.8M	Sell	943,393 -34,908	-4%	-$2.95M	3.76%	1
2020 Q4	$71.6M	Buy	978,301 +63,047	+7%	+$4.69M	3.18%	7
2020 Q3	$71.1M	Buy	915,254 +84,608	+10%	+$5.82M	3.56%	4
2020 Q2	$46.2M	Buy	+830,646	New	+$35.5M	2.76%	6
2017 Q1	–	Sell	-210,000	Closed	-$3.4M	–	111
2016 Q4	$3.4M	Buy	+210,000	New	+$3.81M	0.72%	62
2015 Q4	–	Sell	-185,000	Closed	-$3.67M	–	76
2015 Q3	$3.67M	Buy	185,000 +80,000	+76%	+$2.53M	1.39%	27
2015 Q2	$3.65M	Buy	+105,000	New	+$3.2M	1.27%	29

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Summit Partners Public Asset Management's HZNP Position: Q3 2022 in Review

Summit Partners Public Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 873,803 shares — an estimated $69.7M sold.

Summit Partners Public Asset Management first reported a position in HZNP in Q2 2015 and held it in 12 quarters. The position peaked at $119M in Q3 2021. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Summit Partners Public Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Summit Partners Public Asset Management sold 873,803 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $69.7M.
Summit Partners Public Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and held it in 12 quarters.
Summit Partners Public Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $119M in Q3 2021.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Summit Partners Public Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.